Jazz Pharma (JAZZ): Notes From The Road With Management - Piper Jaffray

Piper Jaffray analyst, David Amsellem, hosted Jazz Pharmaceuticals (NASDAQ: JAZZ) senior management in meetings with investors. He gained insight into the studies evaluating JZP-110, a new chemical entity (NCE) opportunity for the treatment of excessive daytime sleepiness (EDS) associated with narcolepsy and obstructive sleep apnea (OSA). The analyst believes that JAZZ remains on track to report top-line Phase III results before year-end. With strong visibility on steady growth for Xyrem (along with greater visibility on durability in the wake of the recent generic settlements), along with growing contribution from Defitelio and eventually JZP-110. This is expected to translate into a long-term EPS CAGR in at least the mid-to-high teens.

No change to Overweight rating or $186 PT.

For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.

Shares of Jazz Pharmaceuticals closed at $148.96 yesterday.

You May Also Be Interested In

• Keefe, Bruyette & Woods Upgrades Trustmark (TRMK) to Outperform
• Assa Abloy (ASSAB:SS) (ASAZY) PT Raised to SEK275 at Citi
• First Busey (BUSE) PT Lowered to $24 at DA Davidson